SEC Form 4 · accession 0001209191-15-042180
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard F Pops
Director
Period of report
May 11, 2015
Accepted (ET)
May 13, 2015 · 3:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 11, 2015 | M | 15,000 | $4.76 | A | 18,273 | D | |
| Common StockF1 | May 11, 2015 | F | 1,801 | $39.63 | D | 16,472 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option | $4.76 | May 11, 2015 | M | 15,000 | D | May 28, 2008 | May 28, 2015 | Common Stock | 15,000 | 0 | D |
Explanation of responses
- F1The share issuance reported on Table 1 reflects shares issued upon the exercise of options granted on May 28, 2008, which, if unexercised, would have expired on May 28, 2015. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's equity incentive plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($4.76) was subtracted from the May 11, 2015 market close price ($39.63), and this net amount ($34.87) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,199 shares to the optionee. The 1,801 shares underlying the remaining portion of the options are not available for reissuance, and no shares are sold into the market as part of the exercise in connection with a net issuance program.